Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON), has been recognised as an Asia IP Elite for 2025 by Intellectual Asset Management (IAM), the world’s leading publication on intellectual property.
Prestigious Recognition at IPBC Asia 2025
IAM confers this honour on a select group of Asia-based organisations that demonstrate exceptional intellectual property value creation and leadership in the region. The award was presented at IPBC Asia, held in Tokyo from November 18 to 20, 2025.
Legacy of Strong IP Leadership
As per the Biocon Biologics Press release, Biocon first entered the Asia IP Elite list in 2016, becoming the first and only Indian pharmaceutical company to receive this distinction for its robust IP management and sustained value creation. Since then, Biocon Biologics has carried this legacy forward. Together, Biocon and Biocon Biologics remain among the very few Indian pharmaceutical companies to feature consistently on the Asia IP Elite roster. Notably, the 2025 recognition marks their ninth consecutive year on this prestigious list.
Leadership Emphasises Innovation and Access
Commenting on the achievement, Shreehas Tambe, CEO and Managing Director of Biocon Biologics, said that the continued inclusion in the Asia IP Elite list reflects the company’s long-standing commitment to innovation and a strong intellectual property strategy. He added that this recognition reinforces Biocon Biologics’ growing stature as a global biosimilars leader and highlights the critical role of its IP strategy in expanding access to high-quality, affordable therapies for patients worldwide.
Rigorous Selection by IAM
Each year, the IAM editorial team undertakes an extensive research process, combining quantitative data with qualitative assessments. Through this rigorous evaluation, IAM identifies an exclusive group of leading corporations and research institutions for induction into the Asia IP Elite, recognising excellence in intellectual property creation and management.